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Abstract: We report herein the synthesis of six diterpene derivatives, three of which are 
new, generated through known organic chemistry reactions that allowed structural 
modification of the existing natural products kaurenoic acid (1) and copalic acid (2). The 
new compounds were fully characterized using high resolution mass spectrometry, infrared 
spectroscopy, 1H- and 13C-NMR experiments. We also report the evaluation of the  
anti-tuberculosis potential for all compounds, which showed some promising results for 
Micobacterium tuberculosis inhibition. Moreover, the toxicity for each of the most active 
compounds was also assessed. 
Keywords: kaurenoic acid; copalic acid; structural modification; diterpene derivatives;  
anti-tuberculosis activity; cytotoxicity; Mycobacterium tuberculosis 
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1. Introduction  
Tuberculosis (TB) is a widely spread respiratory disease which caused 1.3 million deaths worldwide 
in 2012 [1]. It is considered the second leading cause of death from a single infectious agent, after HIV [1]. 
TB is a bacterial respiratory illness, caused by Micobacterium tuberculosis [2]. It is contagious and 
airborne, which makes it somewhat difficult to avoid or to control. This disease mostly affects the lungs, 
causing coughing, and later leading to chest pains, weakness, weight loss and fever [2]. In 2012,  
8.6 million people contracted TB, among them 530,000 children [1]. Multidrug-resistant TB (MDR-TB) 
is an even worse public health problem due to bacterial resistance to the available anti-tubercular agents. 
This leads to a higher rate of death, compared to regular TB. In 2012, 450,000 people developed  
MDR-TB and 170,000 people died from it in the same year [1], leading to a 37.78% rate of death. In the 
same period the rate of death for TB was 15.12%. The number of people diagnosed with MDR-TB in 2012 
was nearly the double of people diagnosed with it in 2011 [1]. Billions of dollars have been invested and 
are required to finance anti-TB programs. In 2013, the amount invested was 6 billion dollars, and there 
is still a gap of 2 billion per year [1].  
The most important action to eradicate TB is the use of Bacille Calmette-Guerin (BCG) vaccine, the 
only one used to prevent this disease [3]. The policies for applying the BCG vaccine are different around 
the world. Some countries chose a universal vaccination program, while others only recommend it for 
some risk groups [3]. The fact is that this eradication is planned by several countries, but to eliminate 
TB from any country is considered very difficult due to immigration and global travelling [3]. This 
considerably enhances the importance of effective anti-tubercular agents.  
Anti-tubercular drugs are classified as first, second and third-line drugs, where second-line indicates 
a less effective drug or expression of some side effects, and third-line indicates a poorly effective drug [4]. 
Thus, first-line anti-tubercular drugs are the most effective in use nowadays. These drugs are 
streptomycin, isoniazid, pyrazinamide, rifampicin and ethambutol [4]. The standard treatment for TB is 
a six month treatment, involving two months of isoniazid, rifampicin, pyrazinamide and ethambutol in 
the intensive phase, followed by isoniazid and rifampicin in the continuous phase [4]. When we refer to 
MDR-TB, we refer to the resistance to first-line anti-tubercular drugs [4].  
Natural products can be found in a wide plethora of living species, with many of them harnessing the 
potential to possess biological and therapeutic activity of high importance [5,6]. The ever-increasing 
demand for new drug molecules that act against current or new illnesses has led to greater interest in 
research conducted on secondary plant metabolites [7,8]. The isolation of a new compound from its 
natural source and testing its bioactivity is one of the ways, but we wish to focus our research on another 
alternative; isolation of an already known biologically active compound and modifying key chemical 
moieties within the molecule to investigate any changes in its bioactivity. These chemical modifications 
can be performed through biotransformation, utilizing enzymes, or chemically, with the hope of using 
cheap and commercially available reagents, as we have reported previously [9,10].  
Diterpenes are a large class of natural compounds that exhibit a range of interesting biological 
activities such as antimicrobial [11,12], anti-inflammatory [13] gastroprotective [14], anti-spasmodic [15], 
among others [16]. Due to our research interest on structural modification of terpenoids [17,18] and on 
the evaluation of biological activities of natural terpenoids and their semisynthetic derivatives [10,12,19], 
we decided to perform some structural modifications in the natural diterpenes kaurenoic acid (1) and 
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copalic acid (2) (Figure 1), and to evaluate the variation of the anti-tubercular activity of the different 
obtained derivatives. This was proposed taking into account the displayed activities of kauranes [16] and  
labdanes [12], together with the commercial availability of natural sources of kaurenoic acid (1) and 
copalic acid (2). Both substances are the major components in each one’s botanical source, kaurenoic 
acid (1) from Mikania glomerata (aerial parts) and copalic acid (2) from Copaifera langsdorffii 
(oleoresin). Moreover, both compounds have also previously displayed antimicrobial activity [9,11,12]. 
 
Figure 1. Biologically active diterpenes 1 and 2. 
If the proposed structural modifications were to lead to more active compounds, with no expressive 
toxicity, we could contribute to the search for anti-TB and anti-MDR-TB agents. The attempt to improve 
terpenoids activity through structural modification is widely used [20,21] and even inspires some 
company’s business model [22,23]. 
We herein present our research results on submitting those natural substances to high-yielding 
transformations, such as epoxidation, ozonolysis, Baeyer-Villiger and aldol reactions, together with the 
promising anti-tubercular results obtained. Toxicity was also evaluated for the starting materials and 
obtained compounds. 
2. Results and Discussion 
2.1. Diterpenes 
2.1.1. Kaurenoic Acid (1) 
The certified dried and powdered aerial parts of Mikania glomerata were purchased from the 
Brazilian company called “Nutri Comércio de Ervas LTDA”, based on the city of São Paulo—SP. The 
extraction was performed as described in experimental section and the obtained kaurenoic acid (1) was 
identified by NMR experiments. This procedure yielded enough 1 to perform the structural modifications 
and all biological assays. 
2.1.2. Copalic Acid (2) 
The Copaifera langsdorffii Desf. oleoresin (OC, Lot 0790310, manufactured 09/2010) was purchased 
from Apis Flora, a Brazilian herbal company located in the city of Ribeirão Preto—SP, Brazil. The 
description of the extraction is detailed in the experimental section, and the obtained copalic acid (2) 
was identified by NMR data analysis. In this case also a sufficient quantity of the natural product  
was obtained. 
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2.2. Synthetic Modifications 
After successful isolation, compounds 1 and 2 were then subjected to a series of chemical reactions 
aiming to modify the core structure. Six different semisynthetic derivatives were obtained, each 
containing new key moieties that could be evaluated to detect any increases in activity during MIC tests 
against tuberculosis cell lines. Looking firstly at the modifications to kaurenoic acid (1), we report three 
successful reactions (Scheme 1).  
 
Scheme 1. Structural modifications in kaurenoic acid (1). Reagents and Conditions: (i) 1  
(1 equiv.), m-CPBA (2 equiv.), CHCl3, 0 °C, 24 h; (ii) 1 (1 equiv.), O3, CH2Cl2, −72 °C,  
15 min, then (CH3)2S, −72 °C to r.t.; (iii) 4 (1 equiv.), m-CPBA (2 equiv.), r.t., 24 h. 
The epoxidation of kaurenoic acid 1 had previously been reported in the literature [24,25], and the 
reaction proceeded in our lab in 90% yield, affording compound 3 as a colorless oil (Scheme 1, step i). 
Ozonolysis of compound 1 proceeded for 15 min at a reduced temperature to afford the ketone product 
4 as a colorless oil in 85% yield (Scheme 1, step ii). Further reaction of ozonolyis product 4 with  
m-CPBA, at room temperature led to the formation of Baeyer-Villiger product 5 in excellent yield (92%, 
Scheme 1, step iii). Confirmation of each of the products 3, 4 and 5 was achieved through analysis of 
the 1H- and 13C-NMR spectra, along with their IR spectra and further confirmation by high resolution 
mass spectrometry. DEPT-135 and 2D-NMR experiments were also very useful to confirm assignments. 
In special, the position of the inserted oxygen atom in the formation of compound 5 was confirmed 
through the observation of a 1H signal at 4.72 ppm at the 1H-NMR spectrum. 
Looking at our second isolated natural product, copalic acid (2), we devised a number of structural 
modifications to this molecule, either using similar reactions to that applied to kaurenoic acid (1), or 
different reactions altogether (Scheme 2).  
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Scheme 2. Structural modifications in copalic acid (2). Reagents and Conditions: (i) 2  
(1 equiv.), m-CPBA (1.5 equiv.), CHCl3, 0 °C, 24 h; (ii) 2 (1 equiv.), O3, CH2Cl2, −72 °C, 
15 min, then (CH3)2S, −72 °C to r.t.; (iii) KOtBu (12 equiv.) in THF, then 7 (1 equiv.) added, 
r.t., 18 h.  
All reactions tested on copalic acid were successful, furnishing three new structures: the epoxidation 
of 2 was very successful, affording the new epoxide 6 in good yield (87%) (Scheme 2, step i) and the 
ozonolysis of 2 also occurred efficiently, giving the new diketone 7 in a very good yield (92%) (Scheme 2, 
step ii); aldol conditions applied to compound 7 led to the new derivative 8, yielding 89% of product 
(Scheme 2, step iii). 
NMR structural assignment, including comparison with the starting material NMR data, led to the 
confirmation of structures after synthesis. There were performed 1H-NMR, 13C-NMR {1H}, DEPT-135, 
2D-NMR experiments. Further confirmation was also achieved by IR spectroscopy and high resolution 
mass spectrometry. Formation of compound 6 is preferably performed through the insertion of the 
oxygen from the opposite side of the bulky group at the carbon next to the double bond. This is due to 
the volume of m-CPBA itself. A long range coupling between one of the epoxide hydrogens (W 
coupling), which is only possible in the proposed isomer, corroborates the proposed stereochemistry. 
The stereochemistry of the formed ring in compound 8 was assigned on the basis of literature 
information. Van Wyk and co-workers [26] described exactly the same cyclisation starting from the 
enantiomer of compound 7. For the same reasons, the use of compound 7, led to the obtention of the 
enantiomer of van Wyk’s product. In addition, our NMR data are also in agreement with the structure [27]. 
2.3. Biological Assays 
The evaluation of the anti-tubercular potential performed in this work was conducted against the cell 
line Mycobacterium tuberculosis H37Rv, ATCC 27294, in accordance with a strict experimental 
procedure, as described in the experimental section. Isoniazid, nowadays a widely used anti-tubercular 
drug recommended by the WHO [28,29], was used as positive control.  
The first evaluated compounds were the natural ones, compounds 1 and 2, to provide standards for 
evaluation and goals in the search for more active compounds. Both compounds gave a MIC value of 
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125 μg·mL−1, which is unpromising. According to Cantrell [30], only substances with MIC values equal 
or less than 64 μg·mL−1 are considered to be active against mycobacteria. The same author classifies 
substances with MIC values equal or higher than 128 μg·mL−1 as inactive, and describes substances with 
MIC values between 64 and 32 μg·mL−1 as moderately active [30]. We agree with Cantrell, and propose 
here a more detailed and complete scale for the classification of anti-mycobacterial activity, covering all 
ranges (Table 1).  
Table 1: Classification of compounds with anti-mycobacterial activities. 
Activity Level Range of MIC Values (μg·mL−1) 
Inactive 125 and higher 
Weak 80 to 100 
Moderate 31.25 to 64 
Significant 12.5 to 25 
Promising 10 or lower 
The values that define each range were chosen taking into account the different values used in 
different dilution values during different authors’ MIC measurements, seen in review papers that gather 
several values from different articles [30]. Some authors use values from 1000 to 0.49 μg·mL−1, while 
others prefer dilutions from 1600 to 0.78 μg·mL−1. To define the promising range, we also took into 
account the MIC values obtained for the first line anti-tubercular drugs (Table 2). As mentioned, our 
main goal was to reach moderate to significant activities with the modifications, since we are starting 
from inactive substances (with MIC of 125 μg·mL−1). 
Table 2. Results obtained in the anti-tuberculosis potential and toxicity evaluation together 
with reference values for first line drugs. 
Compound 
Obtention MIC  
(μg·mL−1)
MIC  
(μM) 
Toxicity **  
(Cell Viability)Origin Compound Process 
1 ----- Isolation 125 --- ne 
2 ----- Isolation 125 --- ne 
3 1 Epoxidation 100 --- ne 
4 1 Ozonolisis 100 --- ne 
5 4 Baeyer-Villiger 200 --- ne 
6 2 Epoxidation 25 78 97% 
7 2 Ozonolisis 12.5 47.3 96.7% 
8 7 Aldol reaction 6.25 25.36 100% 
Ethambutol * [31] ----- --- 1.64 7.22 --- 
Pyrazinamide [32] ----- --- 3.12 25.34 --- 
Streptomycin [32] ----- --- 6.25 10.75 --- 
Rifampicin [32] ----- --- 0.12 0.15 --- 
Isoniazid ----- --- 0.06 0.44 --- 
* Ethambutol dihydrochloride (EMB.2HCl); ** Evaluated at the active concentration; ne = not evaluated.  
The kaurenoic acid derivatives achieved a part of our objectives, due to the obtainment of lower MIC 
values (see Table 2). Nevertheless, the best results obtained with kaurenoic acid derivatives were MIC 
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values of 100 μg·mL−1, which can only be considered weak activity. This is still far from the significant 
or promising range. Moreover, one of the obtained derivatives (compound 5) presented an even higher 
MIC than the natural product.  
On the other hand, copalic acid derivatives led us to reach our objectives and achieve even better 
results, presenting considerable improvement in activity.  All the copalic acid derivatives presented MIC 
values lower than the kaurenoic acid derivatives. The epoxidation product, compound 6, reached the 
level of significant activity with a MIC value of 25 μg·mL−1, one fifth of the original value (125 μg·mL−1 
for the natural product). An even better result was obtained with compound 7, which presented a MIC 
value of 12.5 μg·mL−1, virtually placing this compound in the promising range. 
The most important result of our work was the achievement of a derivative with the same activity as 
a first line drug. Compound 8 presented a MIC value of 6.25 μg·mL−1, the same value as found for 
streptomycin [32]. This is an important result, since it is the same activity as that presented by a first line 
drug currently in use for anti-tuberculosis treatment (see Table 2).  
Further considerations lead to other interesting insights. When a comparison between compound 8 
and streptomycin is accomplished with MIC values in micromolar concentrations, streptomycin seems 
to be better (10.75 μM) than compound 8 (25.36 μM). Nevertheless, this MIC value in micromolar 
concentrations is equivalent to pyrazinamide (25.34 μM) [32], another first line drug, also currently in 
use in the treatment of TB. In this case, the synthetic derivative (8) equaled the activity of a substance 
that seemed to be substantially better (with MIC value of 3.12 μg·mL−1). Thus, compound 8 equalled 
the anti-tubercular activity of two first line anti-TB drugs, according to the observed MIC values. 
One also has to take into account the toxicity of these anti-TB agents. The three compounds with 
better results for anti-tubercular activity were assayed to evaluate their toxicity. The results are shown 
in Table 2. Compound 8 was evaluated for its cytotoxicity and showed a result of 100% cell viability in 
the concentration of 7.8 μg·mL−1. This indicates that this substance is not toxic at the active concentration.  
3. Experimental Section  
3.1. General Methods 
Unless stated otherwise all reagents were purchased from either Sigma-Aldrich (Gillingham, UK) or 
Alfa-Aesar (Heysham, Lancashire, UK). m-CPBA (57%–86%; Attention! potentially explosive) was 
purified on a 35 g scale by dissolving in 250 mL diethyl ether and washed against saturated sodium 
carbonate solution (3 × 150 mL). The remaining ether was dried (under MgSO4), and remaining solvents 
were removed under reduced pressure affording 17 g of pure m-CPBA [33]. Non-aqueous solvents used 
were pre-dried before use, by distillation under nitrogen over the appropriate drying reagent: 
tetrahydrofuran and petroleum ether (40/60) was distilled over sodium benzophenone ketyl; 
dichloromethane was distilled over calcium hydride. All reactions were performed under an atmosphere 
of nitrogen, with the round bottom flask pre-dried under a flow of nitrogen whilst heating with a flame-gun. 
3.2. General Methods for Substance Analysis 
1H- and 13C-NMR spectra were recorded using a Bruker Avance III spectrometer (operating 
frequency 500.21 MHz for 1H and 125.05 MHz for 13C). Chemical shift values are quoted in parts per 
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million (ppm, δ), and coupling constants J are quoted in Hertz (Hz). High resolution mass spectra 
(HRMS) were obtained from the service provided by the EPSRC Mass Spectrometry Service at the 
University of Swansea. HRMS were run on an LTQ Orbitrap XL instrument as solid samples utilizing 
an ASAP probe. Data were collected using APCl (ionization mode) and FTMS (FT analyzer). Infrared 
spectra were acquired using a PerkinElmer spectrophotometer. Solid samples and liquid samples were 
run neat utilizing the ATR unit of the spectrometer. 
3.3. Anti-Tuberculosis Activity Assay 
The study of antimycobacterial activity of the derivatives obtained was performed in LAPEMA 
(Research Laboratory of Applied Microbiology)—UNIFRAN, under the responsibility of Carlos 
Henrique Gomes Martins, developer for the tests. The activity was determined by the minimum 
inhibitory concentration (MIC). The MIC is defined as the lowest concentration of antimicrobial agent 
that completely inhibits bacterial growth. The MIC values were determined in triplicate using the 
microdilution technique on a REMA, adapted from a procedure reported in the literature [34].  
One milligram of each diterpene was dissolved in 125 μL of dimethylsulfoxide (DMSO) and 1875 μL 
of Mueller Hinton broth was added. The final concentration of DMSO did not exceed 5% and the 
percentage of this solution was used as negative control. With the aid of a sterilized platinum loop, the 
24-hour cultures of microorganisms were taken and transferred to tubes containing 10 mL of sterile 
saline solution. The suspension was standardized by comparing it with the McFarland tube 0.5 (0.1 mL 
of a 1% solution of BaCl2 in 9.9 mL of a 1% H2SO4). Then, serial dilutions in saline and finally in 
Mueller Hinton were performed to provide an inoculum of 5 × 105 CFU/mL (colony forming unit/mL). 
Microplates with 96 holes were sterilized, and a total of 100 μL Mueller Hinton was added, with 
suspensions of micro-organisms and the solutions of the metabolites to be evaluated. Diterpenes were 
evaluated at different concentrations allowing one to determine the concentration required to inhibit the 
growth of micro-organisms to be evaluated. In one of the holes of each plate was made the control 
culture, which must provide bacterial growth due to the absence of antimicrobial agents. Another hole 
was used for sterility control of the medium and Mueller Hinton, and another one for solvent control 
(DMSO) used to solubilize the diterpenes. As a positive control, it was used isoniazid. 
The plates were incubated at 37 °C for 24 h. Subsequently, to each well it was added 30 μL of 0.02% 
aqueous solution of resazurin. After waiting for 18 h, the presence of blue coloration (coloring resazurin 
solution) was interpreted as lack of bacterial growth and pink color signifies the presence of  
viable micro-organisms.  
3.4. Natural Products Extraction 
3.4.1. Kaurenoic Acid 
A portion (1 kg) from a commercial sample of the dried and ground aerial parts of Mikania glomerata 
was extracted portion wise in beaker with dichloromethane under ultrasound. The mixture was then 
filtered and the solvent was removed by rotary evaporation under reduced pressure. The solvent was 
recovered from the process and reused. This portion of plant yielded 42 g of crude extract, which was 
suspended in 300 mL of a 9:1 mixture of MeOH/H2O (v/v) and filtered through filter paper. The soluble 
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portion was partitioned with n-hexane (4 × 300 mL) and dichloromethane (2 × 300 mL) and both 
fractions had their solvent removed by rotary evaporation. The n-hexane fraction, containing most of 1 
was subjected to vacuum liquid chromatography (VLC) with n-hexane/EtOAc mixtures with increasing 
gradient of polarity, thereby obtaining 12 fractions. Fractions with large quantities of 1 were purified by 
open classic column chromatography (CCC) (n-hexane/EtOAc 9:1), resulting in 900 mg of kaurenoic acid. 
3.4.2. Copalic Acid 
A sample (30 g) of the purchased C. langsdorffii oilresin was incorporated to 60 g of silica gel 60 and 
submitted to a vacuum liquid chromatography (VLC) with 380 g of silica gel (60 and 60H, 50% each), 
according to the adaptation method [35]. As eluent were used n-hexane/EtOAc mixtures with increasing 
gradient of polarity, thereby obtaining 7 fractions. Fractions with great quantities of 2 were purified by 
classic column chromatography (CCC) (n-hexane/EtOAc 9:1), resulting in 5.5 g of copalic acid (2). 
3.5. Individual Experiments 
(2R,4'R,4a'S,6a'S,9'R,11a'R,11b'S)-4',11b'-Dimethyldodecahydro-7'H-spiro[oxirane-2,8'-[6a,9] 
methanocyclohepta[a]naphthalene]-4'-carboxylic acid (3): A sample of kaurenoic acid (1, 0.1 g,  
0.33 mmol) and chloroform (10 mL) were added to a 50 mL test tube, and the solution was stirred and 
then cooled to 0 °C. Whilst the temperature was maintained at 0 °C, purified m-CPBA (0.11 g,  
0.66 mmol) was added in one portion, and the reaction was kept stirring for 24 h at 0 °C. The reaction 
was quenched by the addition of saturated sodium hydrogen carbonate solution (20 mL). The organic 
layer was separated, and was subsequently submitted to consecutive washings with saturated sodium 
hydrogen carbonate solution (5 × 20 mL). The organic layer was dried over MgSO4, and the remaining 
solvents were removed under reduced pressure, affording the title compound 3 (0.094 g, 90%) as a pure 
colourless oil without any need for further purification. ATR-FTIR νmax/cm−1: 2936, 2253, 1691, 1460, 
1265, 910. 1H-NMR (CDCl3, 500 MHz, δ ppm): 2.82 (d, 1H, J = 4.7 Hz), 2.74 (d, 1H, J = 4.7 Hz),  
2.14–2.09 (m, 1H), 2.01–1.97 (m, 1H), 1.89–1.77 (m, 4H), 1.76–1.71 (m, 1H), 1.70–1.65 (m, 2H),  
1.64–1.61 (m, 3H), 1.60–1.56 (m, 1H), 1.52–1.46 (m, 2H), 1.45–1.41 (m, 2H), 1.40–1.36 (m, 2H), 1.18 
(s, 3H), 1.05–0.98 (m, 2H), 0.90 (s, 3H), 0.76 (m, 1H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 183.7, 66.6, 
57.1, 55.2, 50.6, 48.9, 45.6, 43.9, 42.7, 41.4, 40.9, 39.9, 38.7, 38.0, 29.23, 29.16, 22.0, 19.8, 19.3, 16.0. 
HRMS: [C20H30O3 − H]− requires 317.2122; Found 317.2118 [M − H]−. 
(4R,4aS,6aS,9R,11aR,11bS)-4,11b-Dimethyl-8-oxotetradecahydro-6a,9-methanocyclohepta[a] 
naphthalene-4-carboxylic acid (4): To a pre-dried 100 mL round bottom flask, kaurenoic acid 1 (0.1 g, 
0.33 mmol) and anhydrous dichloromethane (20 mL) were added. Under stirring, the solution was cooled 
to −72 °C (dry ice/ethanol) and, after 30 min, a stream of oxygen/ozone was passed through the solution 
maintained at −72 °C. Then, a steady stream of ozone (O3) was bubbled through this solution (10 min) 
until the solution became pale blue in colour. Gaseous oxygen was then purged into the system to remove 
ozone excess. Dimethylsulfide was then added to the resulting mixture at −72 °C, and the mixture was 
kept stirring for 30 min, while it was warmed to room temperature. Saturated sodium hydrogen carbonate 
solution (50 mL) was then added to the reaction mixture, and the aqueous layer was extracted with 
dichloromethane (3 × 50 mL). The combined organic extracts were dried over MgSO4, and then 
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remaining organic solvents were removed under reduced pressure. Purification was achieved by flash 
column chromatography on silica gel using petroleum ether (40/60): ethyl acetate (3:2) as the eluent, 
affording 4 as colourless oil (0.085 g, 85%). ATR-FT IR νmax/cm−1: 2942, 2871, 2252, 1738, 1694, 1399, 
732. 1H-NMR (CDCl3, 500 MHz, δ ppm): 2.34 (dd, 1H, J = 4.3;7.3 Hz), 2.25 (dd, 1H, J = 2.9;12.1 Hz), 
2.15–2.09 (m, 1H), 1.95–1.88 (m, 2H), 1.87–1.80 (m, 4H), 1.79–1.67 (m, 3H), 1.65–1.56 (m, 2H),  
1.55–1.46 (m, 2H), 1.44–1.36 (m, 2H), 1.20 (s, 3H), 1.12 (d, 1H, J = 8.1 Hz), 1.05 (dd, 1H, J = 2.8; 11.5 Hz), 
0.97 (dd, 1H, J = 4.7;13.6 Hz), 0.95 (s, 3H), 0.83–0.73 (m, 1H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 
222.8, 184.1, 56.8, 55.0, 54.0, 47.8, 43.7, 42.5, 41.0, 40.6, 39.8, 37.7, 37.3, 29.5, 29.0, 20.7, 19.0, 18.8, 
16.1. HRMS: [C19H28O3 − H]− requires 303.1966; Found 303.1959 [M − H]−. 
(3R,6aS,8aS,9R,12aS,12bR)-9,12a-Dimethyl-5-oxotetradecahydro-3,6a-methanonaphtho[2,1-d]oxocine- 
9-carboxylic acid (5): The ozonolysis product, compound 4 (0.1 g, 0.33 mmol), was  added to a test tube 
together with dichloromethane (10 mL) at room temperature. To this solution, a sample of m-CPBA  
(0.1 g, 0.66 mmol) was added, and it was kept under stirring at room temperature for 20 h. The reaction 
progress was monitored by thin layer chromatography, and after completion it was quenched using 
saturated sodium hydrogen carbonate solution (20 mL). The aqueous layer was extracted with 
dichloromethane (3 × 50 mL). The organic layers were combined, and then dried over magnesium 
sulphate followed by removal of remaining organic solvents under reduced pressure. The remaining 
residue was purified by open column chromatography on silica gel using petroleum ether: ethyl acetate 
as the eluent in a ratio of 3:2, affording 5 as colourless oil (0.097 g, 92%). ATR-FT IR νmax/cm−1: 2955, 
2873, 2851, 1724, 1692, 1457, 1388, 1237, 1162. 1H-NMR (CDCl3, 500 MHz, δ ppm): 4.72 (m, 1H), 
2.25 (dd, 1H, J = 2.2;18.6 Hz), 2.19–2.12 (m, 2H), 1.91–1.81 (m, 2H), 1.80–1.74 (m, 3H),  
1.73–1.63 (m, 2H), 1.59–1.52 (m, 1H), 1.51–1.47 (m, 2H), 1.47–1.38 (m, 2H), 1.25–1.16 (m, 2H), 1.20 
(s, 3H), 1.06–1.01 (m, 2H), 1.00–0.92 (m, 1H), 0.90 (s, 3H), 0.87–0.78 (m, 1H). 13C-NMR (CDCl3, 125 
MHz, δ ppm): 183.4, 172.5, 76.1, 56.9, 53.4, 48.3, 43.8, 43.2, 41.3, 39.8, 37.7, 34.1, 33.4, 29.2, 29.0, 
20.1, 19.3, 16.63, 16.58. HRMS: [C19H28O4 − H]− requires 319.1915. Found 319.1913 [M − H]−. 
(E)-3-Methyl-5-((1S,2S,4aR,8aR)-5,5,8a-trimethyloctahydro-1H-spiro[naphthalene-2,2'-oxiran]-1-
yl)pent-2-enoic acid (6): To a test tube it was added copalic acid (2, 0.1 g, 0.33 mmol) and chloroform  
(10 mL). This solution was cooled to 0 °C and it was added m-CPBA (0.085 g, 0.5 mmol) to it in one 
portion, under stirring. The solution was kept under stirring for 24 h at 0 °C. The reaction was quenched 
by the addition of saturated sodium hydrogen carbonate solution (20 mL). The organic layer was 
submitted to consecutive washings with saturated sodium hydrogen carbonate solution (5 × 20 mL). It 
was then dried over MgSO4, and the remaining solvents were removed under reduced pressure, affording 
the title compound as pure colourless oil after purification by open column chromatography using 
petroleum ether: ethyl acetate (3:2) as the eluent (0.088 g, 87%). ATR-FT IR νmax/cm−1; 2944, 2868, 
1694, 1640, 1575, 1436, 1255. 1H-NMR (CDCl3, 500 MHz, δ ppm): 5.60 (m, 1H), 2.68 (dd, 1H,  
J = 1.9;4.3 Hz), 2.44 (d, 1H, J = 4.3 Hz), 2.24–2.16 (m, 1H), 2.13–2.08 (m, 1H), 2.06 (d, 1H, J = 1.2 Hz), 
1.87–1.79 (m, 1H), 1.79–1.71 (m, 2H), 1.67– 1.61 (m, 1H), 1.53–1.45 (m, 2H), 1.44–1.37 (m, 3H), 1.19 
(t, 2H, J = 7.2 Hz), 1.16–1.07 (m, 2H), 1.00–0.93 (m, 2H), 0.83 (s, 3H), 0.82–0.77 (m, 2H), 0.76 (s, 3H), 
0.74 (s, 3H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 172.4, 163.9, 115.1, 59.2, 55.2, 53.5, 51.0, 43.0, 42.1, 
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40.6, 39.2, 36.6, 33.7, 33.6, 22.0, 21.8, 20.1, 19.5, 18.9, 14.8. HRMS: [C20H32O3 − H]− requires 319.2279. 
Found 319.2273 [M − H]−. 
(1S,4aR,8aR)-5,5,8a-Trimethyl-1-(3-oxobutyl)octahydronaphthalen-2(1H)-one (7): Copalic acid (2, 0.1 g, 
0.33 mmol) and dry dichloromethane (20 mL) were added to a flame dried round bottom flask, and the 
stirring solution was cooled to −72 °C (dry ice/ethanol). After 30 min at this temperature, a stream of 
oxygen/ozone was passed through the solution at −72 °C. Then, a steady stream of ozone (O3) was 
bubbled through this solution (10 min) until the solution became pale blue in colour. Oxygen gas (O2) 
was then purged into the system to remove excess of ozone. Dimethylsulfide (0.2 mL) was then added 
to the resulting mixture at −72 °C, and the solution was allowed to stir and to warm to room temperature 
for 30 min. Saturated sodium hydrogen carbonate solution (50 mL) was then added to the reaction 
mixture, and the aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined organic 
extracts were dried over MgSO4, and then the remaining organic solvents were removed under reduced 
pressure. Purification was achieved by flash column chromatography on silica gel using petroleum 
ether:ethyl acetate (3:2) as the eluent, affording 7 as a colourless oil (0.080 g, 92%). ATR-FT IR 
νmax/cm−1: 2949, 2869, 1711, 1444, 1164. 1H-NMR (CDCl3, 500 MHz, δ ppm): 2.56–2.49 (m, 1H), 2.34 
(dd, 1H, J = 2.1;4.8 Hz), 2.25–2.17 (m, 1H), 2.12 (dt, 1H, J = 7.5;17.5 Hz), 2.09–2.04 (m, 1H), 2.03 (s, 
3H), 1.77–1.64 (m, 2H), 1.60–1.51 (m, 2H), 1.53–1.47 (m, 2H), 1.46–1.39 (m, 2H), 1.38–1.31 (m, 1H), 
1.20–1.09 (m, 2H), 0.89 (s, 3H), 0.78 (s, 3H), 0.66 (s, 3H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 212.6, 
209.5, 63.4, 54.4, 43.0, 42.9, 42.8, 42.0, 39.3, 33.9, 33.7, 30.1, 24.2, 22.0, 19.2, 16.3, 14.8. HRMS: 
[C17H28O2 + H]+ requires 265.2162. Found 265.2162 [M + H]+. 
(4aS,4bR,8aR,10aS)-10a-Hydroxy-4b,8,8-trimethyldodecahydrophenanthren-2(1H)-one (8): To a 150 mL 
round bottom flask were added freshly distilled THF (10 mL) and potassium tert-butoxide (0.5 g,  
4.46 mmol). At this point, a solution of copalic acid ozonolysis product 7 (0.1 g, 0.38 mmol), dissolved 
in distilled THF (5 mL), was added to the initial mixture. The mixture was kept under stirring overnight. 
Upon completion of the reaction (as observed by TLC), the solvent was removed under reduced pressure. 
The residue was dissolved in diethyl ether (10 mL) and washed with H2O acidified with a few drops of 
1M HCl (2 × 5 mL). After the concentration of this new organic layer under reduced pressure, the 
remaining residue was purified by open silica gel column chromatography, using petroleum ether:ethyl 
acetate (4:1) as eluent. Compound 8 was isolated as colorless oil (0.083 g, 89%). ATR-FT IR νmax/cm−1: 
2958, 2927, 2871, 1658, 1461, 1366. 1H-NMR (CDCl3, 500 MHz, δ ppm): 2.38 (m, 1H), 2.33 (dd, 1H, 
J = 0.7;14.2 Hz), 2.25–2.21 (m, 1H), 2.21–2.16 (dd, 1H, J = 2.5;14.2 Hz), 1.92–1.88 (m, 1H), 1.87–1.82 
(m, 1H), 1.78–1.65 (m, 2H), 1.63–1.54 (m, 2H), 1.54–1.50 (m, 2H), 1.50–1.45 (m, 1H), 1.42–1.34 (m, 
2H), 1.12 (m, 2H), 0.93 (s, 3H), 0.83 (s, 3H), 0.80 (s, 3H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 210.9, 
75.8, 57.5, 56.3, 55.5, 42.4, 42.2, 41.7, 40.1, 37.7, 33.9, 33.5, 22.0, 21.7, 18.6, 18.2, 15.5. Due to its 
tertiary alcohol, compound 8 easily undergoes a dehydration reaction in the mass spectrometer’s ionizer. 
Thus, the observed mass is related to its dehydration product: HRMS: [C17H26O + H]+ requires 247.2056. 
Found 247.2055 [M + H]+. 
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3.6. Cytotoxic Assay 
The cytotoxic activity was evaluated using the normal human fibroblast cell line GM07492-A (Coriell 
Cell Repositories, Camden, NJ, USA). Briefly, cells were trypsinized and seeded in 96-well plates at 
concentration of 4 × 104 cells per well in DEMEN medium with HAM-F10 (1:1, v/v) (Sigma-Aldrich®, 
Saint Louis, MO, USA) supplemented with 10% fetal bovine serum (Life Technologies®, Grand Island, 
NY, USA). After 24 h of incubation at 37 °C (CO2 5%), the cell cultures were treated with different 
concentrations of compounds 6, 7 and 8 dissolved in DMSO (1%) at concentrations ranging from 3.12 
to 50 μg·mL−1 and incubated again for another 24 h. Then, the cell viability was assessed using the Cell 
Proliferation Kit II (Roche, Manheim, Germany) according to the manufacturer’s instructions. The cell 
viability was expressed as the percentage of negative control. Doxorubicin 2.17 μM was used as the 
positive control. The tests were performed in duplicate and repeated three times. 
4. Conclusions  
We have shown that structural modifications to pre-existing natural products allow access to new 
analogues that, in turn, can exert a greater activity than the parent natural product when tested against 
tuberculosis cell lines. We have shown that structural modifications of copalic acid (2) through 
consecutive reactions, for example ozonolysis followed by aldol reaction, afforded highly biologically 
active compounds, such as 8, that exhibit MIC values as low as 6.25 μg·mL−1. We have therefore 
achieved the synthesis of a non-toxic compound with an activity comparable to two of the first line drugs 
for tuberculosis treatment.  
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